Good morning, I am Brendan Connors; I am Medifast’s VP of Finance. I am joined today by Michael McDevitt our CEO and CFO. I would like to welcome you to Medifast’s Fourth Quarter and Year End Conference Call for the period ended December 31, 2007. Before we begin I would like to read the following statement. This release contains forward looking statements within the meaning of the Section 27(a) of the Securities Act of 1933 as amended Section 21(e) of the Securities Exchange Act of 1934 as amended in the Private Securities Litigation Reform Act of 1995. These forward looking statements generally can be identified by use of phrases or terminology such as intend, while the similar words or the negative of such terminology. Similar descriptions that manifest objective strategies, plans, goals or targets contained herein are also considered forward looking statements. Medifast believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautioned that these forward looking statements are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others Medifast’s inability to track and retain independent associates and members. Stability and pricing in print, TV and direct mail marketing initiatives affecting the costs to acquire customers. Increasing competition, litigation, regulatory changes and its planned growth in new domestic and international markets and new channels of distribution. Although Medifast believes that the expectations, statements and assumptions reflected in these forward looking statements are reasonable it cautions readers to always consider all these risk factors and end it on a cautionary statements carefully in evaluating each forward looking statement in this release, as well as those set forth in its latest annual report on Form 10-K and quarterly report on Form 10-Q and other filings filed with the United States Securities and Exchange Commission including its current reports on Form 8-K. All these forward looking statements contained herein speak only as of the date of this release. Now I’d like to go over the financial results. The three months ended December 31, 2007, Medifast reported revenue of $19.8 million versus $15.3 million for the same period in 2006, representing an increase of 29%. The direct marketing sales channel accounted for 52% of total revenue, Take Shape for Life 38%, doctors 4% and clinics 6%. As compared to the fourth quarter of 2006 the direct marketing sales channel revenues increased by 6%, Take Shape for Life sales which are fueled by person to person recruiting and support increased by 32% year over year. The company’s clinic division, which began operating under the Medifast Weight Control Center name in late 2006 increased sales by 32% as compared to the first quarter of 2006 and sales to doctors decreased by 10%. The company has selling, general and administrative expenses of $13.5 million in the fourth quarter of 2007 which was an increase of $2.4 million from the prior year. The largest increases in SG&A expense were attributed to increased advertising, increased take shape life commission expense that directly relates to sales as well as additional salaries. Advertising expense for Q4 of 2007 was approximately $3.3 million compared to $2.6 million for the same period last year, an increase of $700,000. The fourth quarter, the company ran advertising tests on television, print and online media highlight our celebrities at the beginning stages of their weight loss program. Because of its proven effectiveness the company invested in a new campaign the first quarter of 2008 which showcases the women’s significant weight loss on the Medifast program. Take Shape Life commission expenses which is directly related to sales growth increased by $900,000 as compared to the fourth quarter of 2006. Salaries and benefits increased by approximately $300,000 as compared with the fourth quarter of 2006. As the company hired additional expertise in critical areas in order to assist in future growth. Salaries are attributed to investing of internal abilities to include capabilities of the company moving forward. These internal teams are associated with the building of several areas including the additional major enhancements of the company’s website, ERP system, call center, nutrition and R&D. The company believes that the enhancements to these critical business functions will significantly improve its customer attention strategies while positively impacting the lifetime value of consumers in providing clearer future revenue expectations from reoccurring customers. The fourth quarter of 2007 the company reported net income of $601,000 or $0.05 per basic share, $0.04 per diluted share compared to $252,000 or $0.02 per basic share, $0.02 per diluted share for the fourth quarter of 2006. Fourth quarter of 2007 represented the company’s 33rd consecutive quarter of profitability. The year ended December 31, 2007 Medifast had revenue of $83.8 million representing a 13% increase compared to $74.1 million reported the year ended December 31, 2006. The company had selling, general and administrative expenses of $56.6 million for the year ended December 31, 2007, which was an increase of $8.1 million from $48.5 million in 2006. As already discussed the majority of the impact resulted from increased advertising spend, increased Take Shape for Life commission’s expense, sales growth and additional personnel expense. The company reported net income of $3.8 million for the year ended December 31, 2007 or $0.30 per basic share, $0.28 per diluted share versus $5.2 million or $0.41 per basic share, $0.38 per diluted share in 2006. The company’s balance sheet remains strong with stockholders equity of $32.4 million and working capital of $10.4 million at December 31, 2007 compared to $27.9 million and $9.6 million at December 31, 2006 respectively. Now I would like to turn the call over to Medifast’s CEO Michael McDevitt.